ASRT - Assertio Therapeutics Inc

ASRT - Assertio Therapeutics Inc

https://www.assertiotx.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025

GlobeNewswire • 1 week, 5 days ago • score: 0.08

LAKE FOREST, Ill., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Assertio Holdings, Inc. ( "Assertio" or the "Company" ) ( Nasdaq: ASRT ) announced that members of its management team will host investor meetings at two investor conferences in New York City during September 2025.

Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025 - Assertio Holdings ( NASDAQ:ASRT )

Benzinga • 1 week, 5 days ago • score: 0.07

LAKE FOREST, Ill., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Assertio Holdings, Inc. ( "Assertio" or the "Company" ) ASRT announced that members of its management team will host investor meetings at two investor conferences in New York City during September 2025.

New Strong Sell Stocks for August 26th

Zacks Commentary • 2 weeks, 6 days ago • score: -0.21

ASRT, BSM and JJSF have been added to the Zacks Rank #5 (Strong Sell) List on August 26, 2025.

Assertio ( ASRT ) Reports Q2 Loss, Beats Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.08

Assertio (ASRT) delivered earnings and revenue surprises of -70.00% and +4.55%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for July 8th

Zacks Commentary • 2 months, 1 week ago • score: -0.50

ASRT, BLIN and BAH have been added to the Zacks Rank #5 (Strong Sell) List on July 8, 2025.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Assertio Holdings, Inc., a commercial pharmaceutical company, provides medications in the areas of neurology, hospital, and pain and inflammation. The company is headquartered in Lake Forest, Illinois.

52W High

$1.38

52W Low

$0.51

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.35

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

8.87

EV/EBITDA (<8 favorable)

4.03

EV/Revenue (<3 favorable)

0.16

P/S (TTM) (<3 favorable)

0.66

P/B (<3 favorable)

0.82

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

2.51%

Institutions (25–75% balanced)

26.86%

Shares Outstanding

96,240,000

Float

85,581,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

117,099,000

Gross Profit (TTM)

77,375,000

EPS (TTM)

-0.45

Profit Margin (>10% good)

-0.37%

Operating Margin (TTM) (higher better)

-0.15%

ROE (TTM) (>15% strong)

-0.38%

EPS YoY (Quarterly) (>10% good)

-0.19

Revenue YoY (Quarterly) (>8% good)

-0.06

Momentum

Bearish momentum

Value

0.0178

Previous

0.0187

Trend

Falling

Signal Cross

No cross

As of

Sep. 11, 2025